Special Guest · 8:00–8:15 AM PT
OP
Olyvia Phillips · Matter Health
Q2 regional spotlight: Chicago, IL ecosystem — AbbVie, Abbott, Baxter, Charles River Labs. World-class medical institutions + strong manufacturing capabilities spanning devices, diagnostics, digital health.
Pitches · 8:15–9:30 AM PT
Vivifi Medical Inc
Tushar Sharma, CEO · tushar@vivifimedical.com
Round
$3M Convertible Note @ $9M Post money Cap, 20% discount
Closed
$1.5M
FDA milestone
9 patient data to prove MoA, showing outcomes superior to other BPH MIS treatments
FDA timeline
2028-2029 (BPH approvals require RCT pivotal studies, as per FDA guidance)
Other groups in round
RobinHood Ventures, Elevate Capital, TMC Venture Fund, Baylor Angel Network, C3 Ventures
DD package
Yes
Traction: 9 patient data, endorsements from top names in Urology and Medtech
What they're looking for: Looking for advisors with experience in out of pocket sales and reimbursement experience
After the session
Investor sentiment
High interest
4
Medium interest
13
Low interest
3
No interest
2
22 responses
Investor engagement
4
Invitations to connect
10
Invitations to apply
Tenomix Inc
Dr. Saumik Biswas, CEO · saumik.biswas@tenomix.com
Tenomix’s technology is a bench-top device that uses robotics, ultrasound and AI to autonomously identify and mark lymph nodes in surgically removed cancer tissues, which improves specimen throughput, reduces pathology lab costs, creates better workflow efficiency and ensures accurate cancer staging.
Round
$5 Million Priced Round @ $12M pre-money
Closed
$4 million total earmarked: 2 million (hard commitment) + 2 million (earmarked)
FDA milestone
1st Pre-submission to FDA completed April 2025, 2nd pre-submission to the FDA submitted; meeting with FDA in March.
FDA timeline
FDA submission in Q2-2027 and FDA approval by Q4-2027.
Other groups in round
We are also in discussion with 16 other investor groups.
DD package
Yes, can be available upon request by current investors.
Traction: Mayo Clinic (Rochester, MN) – Multi-year collaboration including a completed pilot study funded through the competitive ADL RFA program and a new second study being planned to expand clinical data, economic modeling, and head-to-head workflow comparisons. Results were published in a peer-reviewed journal (Frontiers in Medicine). Western University / University Hospital (London, ON) – Data collection study has recently begun. 75 patient study commenced in Q1 2026. St. Paul’s Hospital (Vancouver, BC) – Clinical partner. Beth Israel Deaconess Medical Center (BIDMC, Boston) – early engagement. Houston Methodist (Houston, TX) – exploratory discussions.
What they're looking for: KOLs/clinical champions introductions; hospital introductions; procurement/finance connections; commercialization advisors; strategic partners/investors in pathology, robotics, AI, ultrasound.
After the session
Investor sentiment
Medium interest
2
Low interest
2
No interest
12
16 responses
Investor engagement
1
Invitations to connect
1
Invitations to apply
Sub-Q Bionics
Jordan Pollack, CEO · jordan.pollack@subqbionics.com
Sub-Q Bionics is a pioneering MedTech company developing the world's first fully implantable bionic lymphatic drainage system. The product is designed to treat lymphedema, a chronic and progressive condition affecting the quality of life of millions of women worldwide, especially cancer survivors who have undergone lymph node removal. The system consists of an implantable bionic pump (positioned below the ribcage) with tubing and a microporous ceramic filter that actively drains lymphatic fluid from affected limbs to the peritoneal cavity. The system connects to a cloud-based platform with AI-powered analytics, enabling patients to return to normal life without lifelong dependence on compression garments.
Round
5,000,000 USD Priced Round @ 14,000,000
Closed
2,000,000
FDA milestone
Pre-clinical animal studies complete
FDA timeline
2031
Other groups in round
Yeda Research and Development Co, University of Michigan Biomedical Venture Fund
DD package
in process, some available
Traction: Collaboration Agreement and LOI from Mayo Clinic
What they're looking for: KOL's, GTM evaluation, consultants
After the session
Investor sentiment
High interest
1
Medium interest
1
Low interest
4
No interest
15
21 responses
Investor engagement
1
Invitations to connect